Katie T B Touma1, Allysa M Zoucha1, Jonathan R Scarff1. 1. Drs. Touma and Zoucha are with William Jennings Bryan Dorn VA Medical Center, Anderson Community Based Outpatient Clinic, Anderson, South Carolina, and Dr. Scarff is with William Jennings Bryan Dorn VA Medical Center, Spartanburg Community Based Outpatient Clinic Spartanburg, South Carolina.
Abstract
Objective: The objective of this review is to discuss triiodothyronine's (T3, liothyronine) mechanism of action, efficacy in enhancement and augmentation trials, and dosing and safety considerations for the treatment of depression. Method: A literature search of PubMed was performed using search terms depression, augmentation, antidepressant, and liothyronine. Only English-language studies of subjects with unipolar depression were included from the past 50 years. Results: Most studies have shown that liothyronine is an efficacious enhancement and augmentation strategy for depression in combination with antidepressants, primarily tricyclic antidepressants and selective serotonin reuptake inhibitors. Conclusion: With appropriate baseline and follow-up safety monitoring, liothyronine augmentation can be a safe and effective treatment for unipolar depression. Larger studies of longer duration assessing liothyronine efficacy with serotonin norepinephrine reuptake inhibitors and multimodal antidepressants are needed.
Objective: The objective of this review is to discuss triiodothyronine's (T3, liothyronine) mechanism of action, efficacy in enhancement and augmentation trials, and dosing and safety considerations for the treatment of depression. Method: A literature search of PubMed was performed using search terms depression, augmentation, antidepressant, and liothyronine. Only English-language studies of subjects with unipolar depression were included from the past 50 years. Results: Most studies have shown that liothyronine is an efficacious enhancement and augmentation strategy for depression in combination with antidepressants, primarily tricyclic antidepressants and selective serotonin reuptake inhibitors. Conclusion: With appropriate baseline and follow-up safety monitoring, liothyronine augmentation can be a safe and effective treatment for unipolar depression. Larger studies of longer duration assessing liothyronine efficacy with serotonin norepinephrine reuptake inhibitors and multimodal antidepressants are needed.
Authors: L Gyulai; M Bauer; F Garcia-Espana; J Hierholzer; A Baumgartner; A Berghöfer; P C Whybrow Journal: J Affect Disord Date: 2001-10 Impact factor: 4.839
Authors: Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran Journal: J Affect Disord Date: 2009-08-11 Impact factor: 4.839
Authors: Jennifer B Dwyer; Awais Aftab; Rajiv Radhakrishnan; Alik Widge; Carolyn I Rodriguez; Linda L Carpenter; Charles B Nemeroff; William M McDonald; Ned H Kalin Journal: Am J Psychiatry Date: 2020-05-27 Impact factor: 18.112
Authors: Andréa V Maglione; Bruna P P do Nascimento; Miriam O Ribeiro; Talytha J L de Souza; Renata E C da Silva; Monica A Sato; Carlos A A Penatti; Luiz R G Britto; Janaina S de Souza; Rui M B Maciel; Rodrigo Rodrigues da Conceição; Roberto Laureano-Melo; Gisele Giannocco Journal: Metab Brain Dis Date: 2022-08-11 Impact factor: 3.655